OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-05-31-accounts

Oracle Head and Neck Cancer UK Limited

Charity No. 1142037 Company No. 07125497

Report and financial statements

For the year ended

31 May 2025

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

Contents
Page
Reference and administrative information 1
Trustees’ annual report 2
Independent auditors' report 8
Statement of financial activities 12
(incorporating an income and expenditure account)
Balance sheet 13
Statement of cash flows 14
Notes to the financial statements 15

ORACLE HEAD AND NECK CANCER UK LIMITED

Reference and administrative information

For the year ended 31 May 2025

Trustees: Keith Jones - Chair
Gareth Thomas
James Robertson
Dr. Mehmet Sen
Toby Amis
Frances Rhys-Evans (appointed on 4 March 2026)
Jaymit Patel (appointed on 4 March 2026)
Ghassan Alusi (resigned 19 November 2025)
Chief Executive: Tamara Khan
Company number: 07125497
Charity number: 1142037
Registered office: 167-169 Great Portland Street
5th Floor
London
W1W 5PF
Auditors: Goldwins Limited
75 Maygrove Road
West Hampstead
London NW6 2EG
www.goldwins.co.uk
Bankers CAF Bank Ltd
25 Kings Hill Avenue
Kings Hill
West Malling
Kent
ME19 4JQ
Metro Bank PLC
One Southampton Row
London
WC1B 5HA

Page | 1

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

The trustees, who are also directors under company law, present their report and financial statements for the year ended 31 May 2025.

The trustees confirm that the financial statements comply with current statutory requirements and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102.

Objectives and activities

Purposes and aims

The objects of the Charity are for the public benefit to preserve and protect health and to provide relief for individuals affected by head and neck cancer, including without limitation:

  1. by advancing education and promoting and funding research in relation to the causes, prevention, treatment and cure of head and neck cancers, and publishing the useful results of that research;

  2. by providing practical support, information and assistance to individuals affected by head and neck cancer, their carers and family; and

  3. by promoting collaboration and best practice in the treatment and care of individuals affected by head and neck cancers, including (without limitation) through the provision of grants and financial support.

The Trustees confirm they have referred to the guidance produced by the Charity Commission on public benefit when reviewing the charity’s aims and objectives and in planning future activities.

Activities

Oracle Head and Neck Cancer continues to deliver on this mission across 4 areas:

R (Research). A (Awareness). C (Collaboration). E (Experience of the Patient).

These pillars act as a core focus for all the charity sets out to do to overcome the Head and Neck cancer crisis.

Research

We have approved grants for the following research projects:

Audit Feasibility Study

Working alongside a coalition of funders, we are delighted to fund a study which aims to lay the foundations for a national audit of head and neck cancer in England using existing NHS cancer data. By analysing where and how people are diagnosed, how quickly they start treatment, and how outcomes vary across the country, the project will identify important gaps and inequalities in care. We hope this will allow services to be compared, improvements to be targeted, and progress to be tracked over time; ultimately supporting earlier diagnosis, more timely treatment, and better outcomes for people affected by head and neck cancer.

Page | 2

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

Early Detection and Awareness

This qualitative study explores how adults of South Asian heritage understand head and neck cancer, what influences their decisions to seek help and how awareness and early diagnosis could be improved in culturally appropriate ways. The findings will inform the design of culturally sensitive awareness and early detection initiatives that can support earlier presentation, improve access to care and ultimately reduce inequalities in outcomes.

Language Impact Study

This PhD project aims to improve outcomes for people affected by head and neck cancer by identifying how the language used to describe these cancers influences awareness, help-seeking, and patient experience. By examining public discussions, surveying knowledge, and gathering perspectives from patients, families, and clinicians, the study pinpoints where confusing or technical terminology creates misunderstandings, delays diagnosis, or limits access to support, including around HPV-related cancers. The project will produce evidence-based recommendations to improve how head and neck cancers are communicated about, helping to reduce inequalities and improve experiences and outcomes across the cancer pathway.

Laryngeal Cancer Cohort Expansion

The Laryngeal Cancer CoHort (LARCH) is a national research study designed to improve understanding and care of laryngeal (voice box) cancer by collecting detailed clinical information, scans, voice recordings and tumour samples from people newly diagnosed with the disease and following them over time. By expanding LARCH and ensuring long-term follow-up, this project will generate high-quality evidence to improve shared decision making, develop tools for earlier diagnosis and better predict who will benefit from different treatments.

Electrical Nerve Stimulation Pilot Project

This study aims to improve quality of life for people with head and neck cancer who undergo neck dissection surgery, a procedure that commonly damages a nerve controlling shoulder movement and leaves many patients with long-term pain, weakness, and inability to return to work. The project will test whether applying short bursts of electrical stimulation to the injured nerve during surgery can help it recover and prevent shoulder problems. The NHS currently has no effective treatment for this complication; we hope it could lead to a simple, low-cost treatment that reduces disability, speeds recovery and significantly improves long-term outcomes and independence for thousands of patients each year.

Investigating Metabolic Reprogramming

The project aims to discover new treatment options for adenoid cystic carcinoma (ACC), a rare and difficultto-treat salivary gland cancer, by understanding how these tumours rewire their metabolism to grow and resist therapy. Building on promising early work that used a personalised model to identify a three-drug combination that temporarily shrank a patient’s tumour, the study analyses tumour samples from many ACC patients to map shared metabolic weaknesses that can be targeted with drugs. The project seeks to improve survival and quality of life for people with ACC and contribute to broader advances in treatment for rare head and neck cancers.

Page | 3

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

The Impact of Paan and Smokeless Tobacco

The use of paan (betel quid) and smokeless tobacco is common and strongly linked to higher cancer risk. By studying tissue samples from affected patients, the research identifies the molecular changes that characterise paan-related oral cancers and determine how they differ from cancers caused by smoking or alcohol. The findings will also support prevention and awareness efforts around paan and smokeless tobacco use. As the first UK study of its kind, this work has the potential to make a lasting impact on reducing inequalities and improving outcomes for an underserved high-risk population.

Boron Neutron Capture Therapy

This study aims to develop and advance boron neutron capture therapy (BNCT) as a promising and more precise form of radiotherapy for head and neck cancer. Unlike conventional radiotherapy, which can damage healthy tissues and cause severe long-term side effects, BNCT is designed to concentrate radiation within cancer cells, potentially increasing tumour killing while sparing surrounding normal tissue. Using patient-derived tumour models and innovative laboratory systems, the study will explore how head and neck cancer cells respond to BNCT and uncover the biological mechanisms behind its effects. Ultimately, it has the potential to improve survival, reduce treatment-related side effects, and offer patients more effective and kinder treatment options.

Research & Impact Evening

Once again, we held a successful Research Impact evening in April at the Tower Suites where guests heard presentations from clinicians and researchers, as well as a presentation from a patient and a family member. The evening finished with a panel discussion, which gave all attendees the opportunity to ask their own questions. Thanks must go to the whole team at Tower Suites for their support with the event – especially our patron, Tony Matharu.

Awareness

Page | 4

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

Collaboration

Experience of the Patient

Fundraising

Fundraising continued to be a challenge through the year, especially when set against our ambition to fund more ground-breaking research into head and neck cancers.

However, we are fortunate to benefit from some amazing individuals who consistently go above and beyond to support the charity, as well as our committed corporate community and trusts and foundations. We would like to offer our most sincere thanks to everyone who supports the work we undertake on behalf of our patient community.

Page | 5

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

Financial review

Total income for the charity was £648,454 (2024: 498,898). The total distribution of the charity funds was £918,289 (2024: £364,105). Carried forward funds, £46,203 including restricted funds of £29,353.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, the articles of association, and is constituted as a company limited by guarantee, as defined by the Companies Act 2006.

Recruitment and appointment of new trustees

The statutory power of appointing new trustees hereof shall be exercisable by the persons who are for the time being the trustees hereof.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Page | 6

ORACLE HEAD AND NECK CANCER UK LIMITED

Report and financial statements

For the year ended 31 May 2025

In so far as the trustees are aware:

AUDITORS

The auditors, Goldwins Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Approved by the Board of Trustees on and signed on its behalf by:

…………………………………….

Keith Jones

Chair, Trustee

20 April 2026

Page | 7

INDEPENDENT AUDITOR’S REPORT

TO THE MEMBERS OF ORACLE HEAD AND NECK CANCER UK LIMITED

FOR THE YEAR ENDED 31 MAY 2025

Opinion

We have audited the financial statements of Oracle Head and Neck Cancer UK Limited (the ‘charity’) for the year ended 31 May 2025 which comprise the Statement of Financial Activities, the Balance Sheet, Cashflow Statement, and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditorʼs responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCʼs Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to note b of the accounting policies in the financial statements, which indicates that the charity has experienced financial pressures, including reduced income and limited reserves. These events or conditions, along with other matters set forth therein, indicate that a material uncertainty exists that may cast significant doubt on the charity's ability to continue as a going concern.

Our opinion is not modified in respect of this matter.

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Page | 8

INDEPENDENT AUDITOR’S REPORT

TO THE MEMBERS OF ORACLE HEAD AND NECK CANCER UK LIMITED

FOR THE YEAR ENDED 31 MAY 2025

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditorʼs report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the Trustees’ Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as they

Page | 9

INDEPENDENT AUDITOR’S REPORT

TO THE MEMBERS OF ORACLE HEAD AND NECK CANCER UK LIMITED

FOR THE YEAR ENDED 31 MAY 2025

determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Charityʼs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorʼs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Councilʼs website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor’s report.

Page | 10

INDEPENDENT AUDITOR’S REPORT

TO THE MEMBERS OF ORACLE HEAD AND NECK CANCER UK LIMITED

FOR THE YEAR ENDED 31 MAY 2025

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s members as a body, for our audit work, for this report, or for the opinions we have formed.

……………………………….

Anthony Epton (Senior Statutory Auditor)

for and on behalf of Goldwins Limited Statutory Auditor

Chartered Accountants

75 Maygrove Road

West Hampstead London NW6 2EG

22 April 2026

Page | 11

ORACLE HEAD AND NECK CANCER UK LIMITED

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 MAY 2025

Notes
Restricted
Funds
2025
£
INCOME
Total Income
188,542
EXPENDITURE
Costs of raising funds
3
-
4
328,893
Total expenditure
328,893
Net Income (Expenditure) for the year
(140,351)
Reconciliation of Funds
Total Funds brought forward 1 June 2024
115,535
Transfer between funds
41,666
Total funds carried forward at 31 May 2025
16,850
Expenditure on charitable activities and
Governance costs
- costs of generating voluntary and fundraising
income
Fundraising events
-
Investment income
2
-
Donations and legacies
1
188,542		 Unrestricted
Funds
2025
£
883
459,912
317,528
271,868
589,396
(129,484)
200,503
(41,666)
29,353
65,333
393,696		 Total
Funds
2025
£
883
648,454
317,528
600,761
918,289
(269,835)
316,038
-
46,203
65,333
582,238		 Total
Funds
2024
£
3,475
21,052
474,371
498,898
155,306
208,799
364,105
134,793
181,245
-
316,038

The statement of financial activities includes all gains and losses recognised during the year.

All income and expenditure derives from continuing activities.

The notes on pages 15 to 26 form part of these financial statements.

Page | 12

ORACLE HEAD AND NECK CANCER UK LIMITED

BALANCE SHEET

At 31 MAY 2025

Notes
FIXED ASSETS
Tangible
9
CURRENT ASSETS
Debtors
10
Cash at bank and in hand
CREDITORS: Amounts falling
due within one year
11
NET CURRENT ASSETS
TOTAL ASSETS LESS CURRENT LIABILITIES
CREDITORS: Amounts falling due after one year
12
NET ASSETS
FUNDS
Restricted funds
13
Unrestricted funds
14
TOTAL FUNDS		 £
£
166
166
200
257,827
258,027
188,353
69,674
69,840
23,637
46,203
16,850
29,353
46,203
2025		 £
£
450
450
35,000
405,607
440,607
125,019
315,588
316,038
-
£316,038
115,535
200,503
£316,038
2024		 £
£
450
450
35,000
405,607
440,607
125,019
315,588
316,038
-
£316,038
115,535
200,503
£316,038
2024
316,038
-
£316,038
115,535
200,503
£316,038

20 April 2026

These financial statements were approved by the Trustees on the …………………………. and are signed on their behalf by:

_____ Keith Jones

Chairman and Trustee

Company registration No: 07125497

The notes on pages 15 to 26 form part of these financial statements.

Page | 13

ORACLE HEAD AND NECK CANCER UK LIMITED

CASHFLOW STATEMENT

At 31 MAY 2025

2025
2024
£
£
£
£
Net cash used in operating
activities
(148,663)
39,469
(see note below)
Cash inflows from investing
activities
Investment income
883
3,474
Payments to acquire tangible fixed
assets
-
-
Net cash provided by investing
activities
883
3,474
Net change in cash and cash
equivalents
(147,780)
42,943
Cash and cash equivalents at the
start of the year
405,607
362,664
Cash and cash equivalents at the
end of the year
257,827
405,607
Net income (expenditure )
(as per statement of financial
activities)
(269,835)
134,793
Investment income
(883)
(3,474)
Depreciation of tangible assets
284
284
Decrease / (Increase) in debtors
34,800
(21,505)
Increase / (Decrease) in creditors
86,971
(70,629)
Net cash used in operating activities
(148,663)
39,469
Analysis of cash and cash equivalents
Cash in hand
257,827
405,607
Total
257,827
405,607
Note- reconciliation of net expenditure to net cash flow from operating activities		 2025
2024
£
£
£
£
Net cash used in operating
activities
(148,663)
39,469
(see note below)
Cash inflows from investing
activities
Investment income
883
3,474
Payments to acquire tangible fixed
assets
-
-
Net cash provided by investing
activities
883
3,474
Net change in cash and cash
equivalents
(147,780)
42,943
Cash and cash equivalents at the
start of the year
405,607
362,664
Cash and cash equivalents at the
end of the year
257,827
405,607
Net income (expenditure )
(as per statement of financial
activities)
(269,835)
134,793
Investment income
(883)
(3,474)
Depreciation of tangible assets
284
284
Decrease / (Increase) in debtors
34,800
(21,505)
Increase / (Decrease) in creditors
86,971
(70,629)
Net cash used in operating activities
(148,663)
39,469
Analysis of cash and cash equivalents
Cash in hand
257,827
405,607
Total
257,827
405,607
Note- reconciliation of net expenditure to net cash flow from operating activities		 2025
2024
£
£
£
£
Net cash used in operating
activities
(148,663)
39,469
(see note below)
Cash inflows from investing
activities
Investment income
883
3,474
Payments to acquire tangible fixed
assets
-
-
Net cash provided by investing
activities
883
3,474
Net change in cash and cash
equivalents
(147,780)
42,943
Cash and cash equivalents at the
start of the year
405,607
362,664
Cash and cash equivalents at the
end of the year
257,827
405,607
Net income (expenditure )
(as per statement of financial
activities)
(269,835)
134,793
Investment income
(883)
(3,474)
Depreciation of tangible assets
284
284
Decrease / (Increase) in debtors
34,800
(21,505)
Increase / (Decrease) in creditors
86,971
(70,629)
Net cash used in operating activities
(148,663)
39,469
Analysis of cash and cash equivalents
Cash in hand
257,827
405,607
Total
257,827
405,607
Note- reconciliation of net expenditure to net cash flow from operating activities
362,664
405,607
134,793
(3,474)
284
(21,505)
(70,629)
Net income (expenditure )
(as per statement of financial
activities)
Investment income
Depreciation of tangible assets
Decrease / (Increase) in debtors
Increase / (Decrease) in creditors
Net cash used in operating activities
Analysis of cash and cash equivalents
Cash in hand
Total
 (269,835)
(883)
284
34,800
86,971
(148,663)
257,827
257,827
39,469
405,607
405,607

Page | 14

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MAY 2025

1) ACCOUNTING POLICIES

a) Accounting convention

These financial statements are prepared on a going concern basis, under the historical cost convention. The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) including Update Bulletin 1. The Company is a public benefit entity for the purposes of FRS 102 and a registered charity established as a company limited by guarantee and therefore has also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Companies Act 2006.

Oracle Head and Neck Cancer UK Limited meets the definition of a public benefit entity under FRS 102.

The financial statements have been prepared in sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest pound.

b) GOING CONCERN

The Trustees have carefully considered the financial position of the charity and its ability to continue as a going concern. The charity has faced a challenging period during the year, marked by reduced income streams, increasing operating costs, and ongoing uncertainty in the funding environment. These conditions have placed pressure on cash flow and reserves.

Despite these challenges, the Trustees remain committed to ensuring the charity’s sustainability and have taken a number of proactive steps. These include implementing cost control measures, reviewing staffing and operational structures, and prioritising core charitable activities. The Trustees have also intensified efforts to diversify income sources, including pursuing new grant opportunities, strengthening donor engagement and other various fundraising initiatives.

Cash flow forecasts have been prepared covering a period of at least 12 months from the date of approval of the financial statements. These forecasts indicate that, while there are uncertainties, the charity is expected to be able to meet its liabilities as they fall due, provided that planned funding and cost-saving measures are achieved.

The Trustees acknowledge that there are material uncertainties related to future income generation and external economic conditions, which may cast doubt on the charity’s ability to continue as a going concern. However, based on the actions taken and planned, along with the anticipated funding, the Trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable future. Accordingly, the financial statements have been prepared on a going concern basis.

The Trustees will continue to monitor the financial position closely and take further action as necessary to safeguard the charity’s long-term viability.

Page | 15

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MAY 2025

c) Incoming resources

All incoming resources are included in the Statement of Financial Activities when

the charity is entitled to the income, the receipts is probable and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Legacies are recognised following probate and once there is sufficient evidence that receipt is probable and the amount of the legacy receivable can be measured reliability. Where entitlement - to a legacy exits but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met.

- Bank interest is accounted for on an accruals basis.

d) Resources expended and irrecoverable VAT

Resources expended including grants are included in the Statement of Financial Activities on an accruals basis.

Commitment to fund future grants are recognised as liabilities once the obligation has been communicated to the grant recipient. Where there is an annual review or other performance review related conditions which means that t h e charity may withdraw a commitment if the conditions are notmet, the liability is not recognised until the conditions have been fulfiled, and the commitment canno longer be revoked.

Expenditure includes VAT which is not recoverable by the charity.

The majority of costs are attributable to specific charitable activities.

Support costs include central functions and are allocated to cost categories on the basis of staff time spent on those cost categories.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity.

e) Allocation of support costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the Trusts artistic programmes and activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities. Further detail can be found in Note 5.

f) Operating leases

The charity classifies the leasing of office equipment as operating leases, the title remains with the lessor. Rental charges are charged on a straight line basis over the lease period.

g) Tax status

Oracle Cancer Trust has suffered no tax charge, as it is not subject to UK Corporation tax on its charitable activities.

Page | 16

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MAY 2025

h) Fund Accounting

Funds held by the charity are either:

Unrestricted general funds - these are funds that can be used in accordance with the charitable objectives at the discretion of the trustees.

Designated funds - these are funds that are set aside by the trustees out of unrestricted general funds for specific future purposes or projects.

Restricted funds - these are funds that are subject to restrictions on their expenditure imposed by the donor.

i) Fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - Straight line over 3 years

j) Government grants

Government Grants represent funding received from the AMRC for qualifying projects. Funds are recognised on receipt.

k) Financial Instruments

Cash and cash equivalents include cash at banks and in hand and short term deposits with a maturity date of three months or less.

m) Debtors and creditors

Debtors and creditors receivable or payable within one year of the reporting date are carried at their at transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest.

Page | 17

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

1a)
DONATIONS
General donations
restricted
unrestricted funds
Grant funding
restricted
unrestricted funds
Legacies
restricted
unrestricted funds		 2025
£
169,342
386,507
19,200
18,500
-
54,022
647,571		 2024
£
119,473
219,605
124,793
10,500
-
-
474,371

The Trust benefits greatly from the involvement and enthusiastic support of its many volunteers, details of which are given in our annual report. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

2)
INVESTMENT INCOME
Bank interest receivable -
unrestricted funds
3)
Unrestricted
Salaries and Fees
Events
Support Costs allocated (Note 5)
COSTS OF GENERATING VOLUNTARY AND FUNDRAISED
INCOME
Fundraising Costs		 2025
£
883
883
2025
£
53,924
189,320
74,284
317,528		 2024
£
3,475
3,475
2024
£
99,649
13,448
42,209
155,306

Page | 18

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

4)
Research grants
Salaries
Impact delivery
Patient Support
Website
Events
Other Research Costs
Support costs (Note 5)
Governance costs (Note 6)
CHARITABLE ACTIVITIES AND GOVERNANCE COSTS		 2025
£
59,525
181,121
0
11,116
1,821
306,032
11,669
29,477
600,761		 2024
£
2,852
68,979
28,133
5,631
22,300
23,232
9,601
48,071
208,798

All grants are payable to a range of research organisations to cover salaries and expenses of researchers.

During 2025 the charity was paying grants accrued in prior years.

Page | 19

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

5)
SUPPORT COSTS
Sub-contractors
PR consultancy
Printing, postage, stationery and database
Other office, travel and sundry
Recruitment
Allocated to Charitable activities (Note 4)
Allocated to Governance costs (Note 6)		 2025
£
48,900
836
7,258
23,074
8,160
(11,669)
(2,275)
74,284		 2024
£
25,084
7,456
12,160
8,771
0
(9,601)
(1,661)
42,209

Sub-contractors includes the Chief Executive and Operations Manager

The Trust identifies its support costs, it then identifies those costs relating to Governance. The remaining support costs are allocated between Cost of Generating Funds and Goverance costs. Staff and related costs are allocated on a time basis, overheads are allocated in proportion to staff time.

6)
GOVERNANCE COSTS
Bookkeeping and external audit
Legal and other professional
Support costs allocated (Note 5)
7)
NET EXPENDITURE FOR THE YEAR
This is stated after charging (net of VAT):
Fees payable to the Auditor
Depreciation charge for the year		 2025
£
27,202
-
2,275
29,477
2025
£
5,250
284
5,534		 2024
£
27,181
19,229
1,661
48,071
2024
£
5,250
284
5,534

Page | 20

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

8) PERSONNEL

PERSONNEL
Salaries
Employer NI
Pension costs
Total employment costs
The number of higher paid staff withing the following scales
£110,000 - £120,000
£60,000 - £69,999		 2025
259,943
29,346
4,718
294,007
were:
2025
1
-		 2024
159,986
12,512
3,167
175,665
2024
-
2

During the year the average numbers of employees was 5 (2024 : 4)

The key management personnel of the charity comprise the trustees and CEO. The total compensation paid to key management personnel amounted to £136,950 (2024 : £129,999).

No trustee was remunerated in the current or preceeding year. Total key management personnel costs of one (2024: two) individuals.

Page | 21

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

9) TANGIBLE FIXED ASSETS

Cost or Valuation
At 31 May 2024
Additions
Disposals
At 31 May 2025
Depreciation
At 31 May 2024
Charge for the year
Eliminated
At 31 May 2025
Net Book Value
At 31 May 2025
At 31 May 2024		 2025
Computer
Equiment
£
852		 2025
852
402
284
686
166
450

Page | 22

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

10)
DEBTORS
Grant and event debtors
Other debtors and prepayments
11)
CREDITORS - Due within 1 year
Grant accruals
Deferred Income and other accruals
Trade creditors
Social security and other taxes
Other creditors
12)
CREDITORS - Due after 1 year
Grant accruals		 2025
£
-
200
200
2025
£
81,712
11,715
87,788
5,941
1,197
188,353
2025
£
23,637
23,637		 2024
£
5,000
30,000
35,000
2024
£
80,076
7,215
33,092
3,786
850
125,019
2024
£
-
-

Page | 23

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

13) RESTRICTED FUNDS

AMRC for Lin
HPV awareness
PPI projects
Late Effects project
Oncology meeting, York - Merck
Mercers Livery
NaHaNCA Feasibility Study
Sophie/Pemberton#headneckcheck
Sue Sherman (Sheffield)
Oakdale Trust
CHK/AMRC / Mason Le
Page / Get-a-head for
Koteva
AMRC & Swire - Pioneers
of Discovery - supporting
Fleming and Melake
AMRC for Lin
AMRC for Cicero / Sala
AMRC for Marsh
HPV awareness
PPI projects
Young Tongues
Late Effects project
Inequalities project
Oncology meeting, York -
Merck
Mercers Livery
AMRC & Swire - Pioneers of Discovery -
supporting Fleming and Melake
Education (Fellowship / Scholarship)
Sign Away Cancer		 Balance
1 June 2024
£
1,456
16,575
6,750
53,904
5,000
30,000
1,850
-
-
-
-
115,535
Balance
1 June 2023
£
-
16,998
16,814
1,100
-
-
-
-
-
-
-
1,850
36,762
0
0		 Income
£
0
0
0
53,500
0
12,000
0
25,642
-
2,000
188,542
Income
£
30,000
48,965
0
34,078
6,750
53,904
10,569
5,000
25,000
30,000
-
244,266
200
83,000
12,200		 Expenditure
Transfers
Balance
31 May 2025
£
£
£
(1,456)
-
-
(16,575)
-
-
(6,750)
-
-
(97,404)
-
10,000
0
-
5,000
(42,000)
-
-
0
-
1,850
(25,642)
-
-
(41,666)
41,666
-
(2,000)
-
-
(200)
-
-
(83,000) -
-
(12,200) -
-
(328,893)
41,666
16,850
Expenditure
Transfers
Balance
31 May 2024
£
£
£
-
(30,000)
-
(15,340)
(49,167)
1,456
(239)
-
16,575
(1,100)
-
-
(9)
(34,069)
-
-
-
6,750
-
-
53,904
(10,569)
-
-
-
-
5,000
-
(25,000)
-
-
-
30,000
-
-
1,850
(27,257)
(138,236)
115,535

Page | 24

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

14) UNRESTRICTED FUNDS

Designated funds
Blair Hesketh Memorial
General unrestricted funds
Designated funds
Blair Hesketh Memorial
General unrestricted funds		 Balance
1 June 2024
£
60,473
140,030
200,503
Balance
1 June 2023
£
64,793
79,690
144,483		 Income
£
459,912
459,912
Income
£
254,632
254,632		 Expenditure
Transfers
£
(3,960)
(56,513)
(585,436)
14,847
(589,396)
(41,666)
Expenditure
Transfers
£
(4,320)
(332,528)
138,236
(336,848)
138,236		 Balance
31 May 2025
£
-
29,353
29,353
Balance
31 May 2024
£
60,473
140,030
200,503

The Blair Hesketh Memorial Fund has been set up to provide funds for the Blair Hesketh lectures.

15) TRUSTEES' REMUNERATION AND EXPENSES

No trustee received any remuneration or reimbursement for expenses in respect of the current year or preceding period.

16) RELATED PARTY TRANSACTIONS

There are no related party transactions to disclose for 2025 (2024: none). There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

Disclosures relating to Key Management Personnel are detailed in Note 8

Page | 25

ORACLE HEAD AND NECK CANCER UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MAY 2025

17) ANALYSIS OF NET ASSETS BETWEEN FUNDS

Tangible fixed assets
Debtors
Cash at bank and in hand
Creditors due within one
year
Creditors due after one
year
Balance on fund		 Fund
2025
Unrestricted
Designated
Restricted
Total
£
£
£
£
166
-
-
166
200
-
200
76,805
-
181,022
257,827
(24,181)
-
(164,172)
(188,353)
(23,637)
-
-
(23,637)
29,353
-
16,850
46,203

18) CONTROL

The Charity is controlled by the Trustees under the terms of the Trust Deed.

Page | 26